GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGC Pharma Inc (AMEX:IGC) » Definitions » ROIC %
中文

IGC Pharma (IGC Pharma) ROIC %

: -108.69% (As of Dec. 2023)
View and export this data going back to 2006. Start your Free Trial

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. IGC Pharma's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2023 was -108.69%.

As of today (2024-04-23), IGC Pharma's WACC % is 7.68%. IGC Pharma's ROIC % is -92.62% (calculated using TTM income statement data). IGC Pharma earns returns that do not match up to its cost of capital. It will destroy value as it grows.


IGC Pharma ROIC % Historical Data

The historical data trend for IGC Pharma's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IGC Pharma Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -51.75 -56.48 -47.61 -85.34 -80.66

IGC Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -62.29 -115.94 -64.94 -76.99 -108.69

Competitive Comparison

For the Biotechnology subindustry, IGC Pharma's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IGC Pharma ROIC % Distribution

For the Biotechnology industry and Healthcare sector, IGC Pharma's ROIC % distribution charts can be found below:

* The bar in red indicates where IGC Pharma's ROIC % falls into.



IGC Pharma ROIC % Calculation

IGC Pharma's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Mar. 2023 is calculated as:

ROIC % (A: Mar. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Mar. 2022 ) + Invested Capital (A: Mar. 2023 ))/ count )
=-11.571 * ( 1 - 0% )/( (15.393 + 13.298)/ 2 )
=-11.571/14.3455
=-80.66 %

where

IGC Pharma's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2023 is calculated as:

ROIC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-11.992 * ( 1 - 0% )/( (12.833 + 9.233)/ 2 )
=-11.992/11.033
=-108.69 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IGC Pharma  (AMEX:IGC) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, IGC Pharma's WACC % is 7.68%. IGC Pharma's ROIC % is -92.62% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


IGC Pharma ROIC % Related Terms

Thank you for viewing the detailed overview of IGC Pharma's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


IGC Pharma (IGC Pharma) Business Description

Traded in Other Exchanges
Address
10224 Falls Road, Potomac, MD, USA, 20854
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
Executives
James P Moran director 914 SPRING HILL ROAD, MCLEAN VA 22102
John Edward Lynch director 14 PARK AVENUE, REHOBOTH BEACH DE 19971
Richard K Prins director
Ram Mukunda director, officer: Exec. Chairman & CEO
Claudia Grimaldi officer: Vice president and PFO PO BOX 60642, POTOMAC MD 20859
Rohit Goel officer: Manager & PAO PO BOX 60642, POTOMAC MD 20859
John Cherin officer: CFO, Treasurer and PAO 662 LIVE OAK DRIVE, MCLEAN VA 22101
Shu Kwong Ngai director, officer: Interim CFO 4336 MONTGOMERY AVENUE, BETHESDA MD 20814
Ranga C Krishna director 330 THORNTON ROAD, ENGLEWOOD X1 07631
Sudhakar V Shenoy director 10411 MOTOR CITY DRIVE, BETHESDA MD 20817
Suhail Nathani director INDIA GLOBALIZATION CAPITAL, INC., 4336 MONTGOMERY AVE., BETHESDA MD 20814
Nisswa Acquisition Master Fund Ltd. 10 percent owner C/O MAPLES CORPORATE SVCS LIMITED, PO BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Smith Edward B Iii 10 percent owner C/O BRIGHTLINE CAPITAL MANAGEMENT, LLC, 1120 AVE OF THE AMERICAS, SUITE 1505, NEW YORK NY 10036
Ag Ubs 10 percent owner 600 WASHINGTON BLVD., STAMFORD CT 06901
Pine River Master Fund Ltd. 10 percent owner C/O PINE RIVER CAPITAL MANAGEMENT L.P., 601 CARLSON PARKWAY, 7TH FLOOR, MINNETONKA MN 55305

IGC Pharma (IGC Pharma) Headlines

From GuruFocus